This is a preview of subscription content, log in via an institution to check access.
References
Atarashi H, Kuruma A, Ino T, et al. ONO-1101: a new ultrashort acting beta-adrenergic blocker: initial study of efficacy, safety and pharmacokinetics. Cardiovasc Drugs Ther 1993; 7 Suppl. 2: 444
Iguchi S, Iwamura H, Nishizaki M, et al. Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101. Chem Pharm Bull 1992; 40: 1462–9
Yoshiya I, Ogawa R, Okumura F, et al. Clinical evaluation of landiolol hydrochloride (ONO-1101) on perioperative supraventricular tachyarrhythmia: a phase III, double-blind study in comparison with placebo [in Japanese]. Rinsho Iyaku 1997; 13: 4949–78
Kato K, Iinuma H, Hayakawa H, et al. Clinical effect of intravenous infusion of landiolol hydrochloride (ONO-1101) on paroxysmal atrial fibrillation and atrial flutter: a phase III, double-blind study in comparison with placebo [in Japanese]. Rinsho Iyaku 1997; 13: 4903–24
Rights and permissions
About this article
Cite this article
Landiolol. Drugs in R&D 1, 317–318 (1999). https://doi.org/10.2165/00126839-199901040-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199901040-00007